MiniMed's first standalone quarter: sales up 17% to $843M, breakeven net income, $207M cash

Filed September 8, 2026 · Period ending July 31, 2026 · ~1 min read

Key Changes

• high

  Net sales rose 17% to $843 million, driven by international growth of 18% and U.S. growth of 13%; an extra fiscal week added 4-6 points.

  MD&A: Revenue verify on EDGAR →
• high

  Net income attributable to the company was breakeven, versus a $19 million net loss a year earlier, helped by a $2 million litigation reversal instead of a $17 million charge.

  Notes: Profitability view on EDGAR →
• high

  Gross margin fell 1.5 points to 55.1% as higher-margin legacy sensors gave way to lower-margin Simplera sensors; management expects continued pressure.

  MD&A: Gross Margin verify on EDGAR →